These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 15751773

  • 1. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E, Samudrala R.
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [Abstract] [Full Text] [Related]

  • 2. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.
    Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623
    [Abstract] [Full Text] [Related]

  • 3. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 4. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD, Kagan RM, Heseltine PN, Ramnarayan K.
    Protein Sci; 2003 Aug 28; 12(8):1706-18. PubMed ID: 12876320
    [Abstract] [Full Text] [Related]

  • 5. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS, Sharma A, Kumar R, Gupta P, Garg P, Arora SK.
    Antiviral Res; 2011 Nov 28; 92(2):213-8. PubMed ID: 21875619
    [Abstract] [Full Text] [Related]

  • 6. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M, Bray J, Rezácová P, Sasková K, Brynda J, Pokorná J, Mammano F, Rulísek L, Konvalinka J.
    J Mol Biol; 2007 Dec 07; 374(4):1005-16. PubMed ID: 17977555
    [Abstract] [Full Text] [Related]

  • 7. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V.
    J Chem Inf Model; 2009 Jul 07; 49(7):1751-61. PubMed ID: 19537723
    [Abstract] [Full Text] [Related]

  • 8. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK, Raffa JD, Grebely J, Viljoen M, Mead A, Khara M, McLean M, Krishnamurthy A, DeVlaming S, Conway B.
    Int J Infect Dis; 2009 Sep 07; 13(5):577-83. PubMed ID: 19111493
    [Abstract] [Full Text] [Related]

  • 9. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.
    J Clin Virol; 2006 Apr 07; 35(4):414-9. PubMed ID: 16280255
    [Abstract] [Full Text] [Related]

  • 10. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.
    Wang D, Larder B.
    J Infect Dis; 2003 Sep 01; 188(5):653-60. PubMed ID: 12934180
    [Abstract] [Full Text] [Related]

  • 11. Bioinformatics approach to predicting HIV drug resistance.
    Cordes F, Kaiser R, Selbig J.
    Expert Rev Mol Diagn; 2006 Mar 01; 6(2):207-15. PubMed ID: 16512780
    [Abstract] [Full Text] [Related]

  • 12. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
    Hu GD, Zhu T, Zhang SL, Wang D, Zhang QG.
    Eur J Med Chem; 2010 Jan 01; 45(1):227-35. PubMed ID: 19910081
    [Abstract] [Full Text] [Related]

  • 13. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
    Gianotti N, Tambussi G, Boeri E, Lazzarin A.
    J Biol Regul Homeost Agents; 2001 Jan 01; 15(2):166-9. PubMed ID: 11501975
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B, Cicero ML, Vigano' O, Sirianni F, Ferramosca S, Vitiello P, Di Vincenzo P, Pia De Pasquale M, Galli M, Rusconi S.
    J Clin Virol; 2008 Feb 01; 41(2):154-9. PubMed ID: 18024202
    [Abstract] [Full Text] [Related]

  • 16. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO, Batista PR, Costa MG, Dardenne LE, Pascutti PG, Soares MA.
    J Mol Graph Model; 2010 Sep 01; 29(2):137-47. PubMed ID: 20541446
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
    Aruksakunwong O, Wolschann P, Hannongbua S, Sompornpisut P.
    J Chem Inf Model; 2006 Sep 01; 46(5):2085-92. PubMed ID: 16995739
    [Abstract] [Full Text] [Related]

  • 20. Genotype dependent QSAR for HIV-1 protease inhibition.
    Boutton CW, De Bondt HL, De Jonge MR.
    J Med Chem; 2005 Mar 24; 48(6):2115-20. PubMed ID: 15771454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.